Lupin

Part of MojoOne Strategy

Market Cap: Mid Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE326A01037
NSEID: LUPIN
BSEID: 500257
View on NSE | View on BSE

INR

2,347.60

15.8 (0.68%)

BSENSE

Mar 25

BSE+NSE Vol: 11.77 lacs

Access older stock analysis version

Company CV

About Lupin Ltd.

Lupin Ltd.

Mid Cap

Pharmaceuticals & Biotechnology

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Company Coordinates

Company Details

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E Mumbai Maharashtra : 400055

Tel: 91-22-6640 2323

http://www.lupin.com

info@lupin.com

Registrar Details

Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai

Capital Structure

Present Equity Capital

INR 91.23 Cr

Number of Shares

45.61 Cr

Face Value

INR 2.0

Date

Number
of Shares(Cr)

Equity
Capital (Rs Cr)

Shares Added

Face Value (Rs)

Reason

27-Aug-2024

45.61

91.23

121150

Issued under ESOP Scheme

25-Jul-2024

45.6

91.20

57384

Issued under ESOP Scheme

08-Jul-2024

45.6

91.19

42932

Issued under ESOP Scheme

20-Jun-2024

45.59

91.18

43475

Issued under ESOP Scheme

20-May-2024

45.59

91.17

122374

Issued under ESOP Scheme

17-Apr-2024

45.58

91.15

59809

Issued under ESOP Scheme

02-Apr-2024

45.57

91.14

11387

Issued under ESOP Scheme

20-Mar-2024

45.57

91.14

52041

Issued under ESOP Scheme

21-Feb-2024

45.56

91.13

137917

Issued under ESOP Scheme

23-Jan-2024

45.55

91.10

162400

Issued under ESOP Scheme

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 38 Schemes (18.01%)

FIIs

Held by 870 FIIs (21.49%)

Promoter with highest holding

Lupin Investments Private Limited (45.36%)

Highest Public shareholder

Hdfc Trustee Company Ltd. A/c Hdfc Balanced Advantage Fund (4.59%)

Individual Investors Holdings

5.1%

Board of Directors

Period

Management

Designation

Remuneration

M D Gupta

Chairman (Non-Executive)

14.5 lacs

Nilesh Deshbandhu Gupta.

Managing Director

4.96 cr

Vinita Gupta

Director & Chief Executive Off

10.92 cr

R V Satam

Company Sec. & Compli. Officer

Jean-Luc Belingard

Independent Director

13.9 lacs

Ramesh Swaminathan

Executive Director & CFO

7.74 cr

Mark D McDade

Independent Director

14.5 lacs

K B S Anand

Independent Director

15.7 lacs

Punita Kumar Sinha

Independent Director

16.5 lacs

Raw Materials

Raw Materials Dashboard

Raw Materials

Amount(Rs Cr)

% of RM Cost

No Data Available for Raw Material Segmentation

No Data Available

Finished Goods

Finished Goods Dashboard

Finished Goods

Amount(Rs Cr)

% of Sales Turnover

Pharmaceuticals

10,657.30

93.84%

Income from Research Services

374.24

3.30%

Other Operating Revenue - Export Benefits and Other Incentives

250.66

2.21%

Pharmaceuticals

Income from Research Services

Other Operating Revenue - Export Benefits and Other Incentives

Stock DNA

Revenue and Profits:

Net Sales:

7,168 Cr

(Quarterly Results - Dec 2025)

Net Profit:

1,176 Cr

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 107,046 Cr (Mid Cap)

P/E

22.00

Industry P/E

Dividend Yield

0.52%

Debt Equity

0.00

Return on Equity

22.03%

Price to Book

5.41